After hours, the FDA approved both Vascepa (formally AMR101) and Rayos. Let’s tackle Horizon first.
Horizon’s Rayos will be its second approved drug behind Duexis, both of which are for rheumatoid arthritis, a huge market. The FDA also opened up the drug for use in COPD, asthma, and psoriatic arthritis. Horizon recently signed up a subsidiary of Covidien (NYSE: COV ) to distribute Duexis, and it wouldn’t be surprising to see that deal extended to Rayos. If the drugs gain traction, it may make Horizon an interesting pick-up for Covidien.
Amarin’s triglyceride fighter, Vascepa, is highly-refined fish oil that aced both of its FDA agreed upon phase 3 trials, meaning approval was about as sure of a thing as we get in this business. Amarin is still waiting to hear whether Vascepa will be granted New Chemical Entity status, giving it a five-year window of exclusivity versus just three years of new product exclusivity. The company’s patents run until 2030, and its superiority to GlaxoSmithKline’s (NYSE: GSK ) near billion-dollar drug, Lovaza, means Amarin should succeed, even after Lovaza goes off patent.
Without a marketing partner, there's already speculation that Amarin could be a buyout candidate, but investors shouldn't put all of their eggs in e xplosive growth stocks -- no matter how good the story seems. For instance, the Dow is loaded with companies with solid dividend payouts and highly-sustainable business models built for the long haul. The stocks highlighted in The Motley Fool's new special FREE report, "The 3 Dow Stocks Dividend Investors Need," all have an X factor that makes them stand out from their illustrious Dow peers, and could make a nice complement to riskier growth stocks. Download it now, for free.